Today Stories

Galt Pharmaceuticals®, a pharmaceutical company committed to enhancing the quality of life of patients with products that meet unmet clinical needs, has introduced a 4-day work week for its employees. In a LinkedIn post, CEO and Co-Founder Barry Patel said, “We are not big pharma and are actually looking to disrupt the inefficient big pharma model. We know we can’t always offer the big pharma perks, but we can offer work-life balance and a family-first culture.” About Galt Pharmaceuticals® Galt Pharmaceuticals® has found a better way to enhance the quality of life of patients with products that answer unmet clinical needs, while creating life-changing opportunities for entrepreneurs, our employees and the individuals within the communities we serve. Galt is the first and only company to cr…

- Ultreon™ 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using Artificial Intelligence - The new intuitive interface provides step-by-step guidance to enhance ease of use - When combined with Abbott's Dragonfly OpStar™ imaging catheter and PressureWire X™, the platform provides physicians with a comprehensive set of tools to provide better patient care Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software. This innovative imaging software combines OCT with artificial intelligence (AI) to provide physicians an enhanced, comprehensive view of coronary blood flow…

Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology PARIS and LEXINGTON, Mass – August 3, 2021 – As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion (on a fully dilute…

BioMed X Institute to start two new research programs in the field of autoimmune diseases and drug delivery New research groups in Heidelberg to examine protective tissue factors in autoimmune diseases and the translocation of complex macromolecules across the intestinal epithelial barrier Heidelberg, 02.08.2021. German independent research institute BioMed X announces today the start of two new research projects with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The start of these projects represents a major milestone in the strategic partners’ successful collaboration and addresses two challenging new research areas. Both collaborations were facilitated by Johnson & Johnson Innovation. The new research group PTA (‘Pro…

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses. Through the multi-year collaboration, Kumquat will utilize its small molecule immuno-oncology (IO) platform to discover novel clinical candidates and Lilly has the option to select a certain number of drug candidates for further development and commercialization worldwide, excluding Greater China. Kumquat has retained development and commercialization rights in Greater China for each of the drug candidates selected by Lilly, subject to Lilly's option to co-commercialize in Greater China. Ad…

Collaboration seeks to obtain direct insights from patients to improve clinical trial accessibility, drive efficiency  Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced an innovative partnership with Cancer Hospital Chinese Academy of Medical Sciences (CHCAMS) to develop patient-centric protocol designs and methodologies for decentralized clinical trials in China. The collaboration will also include quantitative research to improve the clinical trial experience of oncology patients. “We are honored to be partnering with CHCAMS,” said Vicky Hsu, Corporate Vice President, Greater China Region Head and Head of Asia/Pacific Biotech Operations for Parexel. “The Cancer Hospital…

28 July 2021 - Today, WHO joins the global community in celebrating World Hepatitis Day with the theme “Hepatitis can’t wait”, calling on all countries to work together to eliminate viral hepatitis as a public health threat by 2030. A hepatitis-free future is achievable with a united effort. Over 354 million people worldwide live with chronic hepatitis; over 8000 new infections of hepatitis B and C occur every day, and more than one million deaths from advanced liver disease and liver cancer occur every year. The 2021 Global report on HIV, viral hepatitis and sexually transmitted infections, took stock of the progress achieved in the last 5 years, the setbacks caused by the pandemic, and the lessons learned for the coming decade.  Although the extent of progress in the hepatitis response h…

Byondis B.V., an independent, clinical stage biopharmaceutical company creating precision medicines, and Glycotope, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, have entered into a platform access agreement to discover and develop antibodies that target specific tumor-associated protein/carbohydrate combined glyco-epitopes (GlycoTargets). Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs). Specific financial terms have not been disclosed. “Selective tumor targeting is key to maximize the potential of our linker-drug platfo…

Translational Science Center for the Healthcare business sector to offer flexible ways of working coupled with the latest technology and equipment New Learning Center will bring all vocational training occupations together under one roof Both construction projects meet the highest sustainability requirements Merck, a leading science and technology company, plans to invest € 270 million at its global headquarters in Darmstadt by building a new Translational Science Center for its Healthcare business sector as well as a new Learning Center. The two construction projects are part of the € 1 billion investment package that Merck announced in March 2019 and plans to realize in Darmstadt by 2025. “Darmstadt is our site of the future. With these investments, we are underscoring the strategic im…

Bachem is pleased to announce that the company has been recognised as one of the five winners of the Swiss Biotech Success Stories Awards 2021. They have been recognised for the value that they have consistently achieved for the past 50 years — a success story based on quality, innovation, sustainability and technological leadership. The company has grown over 50% in the last five years —  operating with sites across the world — and now offer more than 5,500 different biologically active peptides, amino acid derivatives and oligonucleotides.  The prestigious awards, bestowed by the Swiss Biotech Association, celebrate those who have made important and sustainable contributions to the biotech industry in Switzerland. Selected success stories such as Bachem are showcased to illustrate how Sw…

The company employs real-world data and evidence to accelerate research through targeted site and patient recruitment strategies Based on its recent analysis of the global clinical research organization (CRO) market, Frost & Sullivan recognizes leading global CRO Parexel  with the 2021 Global Enabling Technology Leadership Award. Parexel streamlines clients’ clinical development programs, enabling them to navigate market, regulatory, and patient access-related challenges seamlessly. Leveraging a leading suite of end-to-end biopharmaceutical development services covering patient-focused clinical trial design and decentralized clinical trial (DCT) strategies, the company has helped develop 198 of the 200 top-selling biopharmaceuticals in the market. “Parexel employs a dedicated project t…

UK, 19th July 2021 – The Advanced Therapy Treatment Centre (ATTC) network, London Advanced Therapies (LAT) and the Cell and Gene Therapy Catapult (CGTC), in partnership with Health Education England elearning for healthcare, have developed a new eLearning programme targeted at healthcare and academic professionals to support their learning on both the fundamentals and clinical adoption of advanced therapies. This series of eLearning sessions is designed to give the learner a core understanding of advanced therapies, how they function in the body, and the steps involved in delivering these medicines. The modules take the learner from the basics of cell and gene therapy, through to a more in-depth look at products currently being delivered through both commissioned treatments and clinical tr…

Plan aims to unlock up to £400 million of new private investment and create up to 5,000 new highly-skilled jobs over next decade Stevenage could become one of Europe’s largest ‘clusters’ for biotechnology and other early-stage life science companies Vision for campus developed in partnership with Stevenage Bioscience Catalyst, UK Government and Stevenage Borough Council; GSK to make 33 acres of land available for development at the company’s R&D site in Stevenage GSK has today announced that it has formally started the process of seeking a development partner to transform land within the company’s existing 92-acre Research & Development site in Stevenage into one of Europe’s largest ‘clusters’ for biotechnology and other early-stage life science companies. The vision for the new…

Eli Lilly and Company (NYSE: LLY) today announced the acquisition of Protomer Technologies ("Protomer"), a private biotech company. Protomer's proprietary peptide- and protein-engineering platform is used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity.   The potential value of the transaction is over $1 billion, with successful achievement of future development and commercial milestones. Lilly previously led an equity investment in Protomer alongside the JDRF T1D Fund, providing Lilly with 14 percent ownership of the company. Lilly is acquiring the remainder of the stock of Protomer beyond its initial investment. Founded in 2015 and based in Pasadena, California, Protomer is engineering next-generation protein therapeutics tha…

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of its collaboration with My Green Lab, a non-profit organization committed to improving the environmental sustainability of scientific research. The company has set a goal to obtain Accountability, Consistency and Transparency (ACT) labelling for its entire cold temperature storage portfolio by the end of 2021. Over time, Thermo Fisher expects to ACT label more than 1,200 additional SKUs, enabling research, pharmaceutical and clinical laboratories to achieve their sustainability objectives by providing a broader range of purchasing options. "Our customers are committed to adopting more sustainable laboratory practices, and My Green Lab enables them to take proactive steps to meet th…

Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars , including 100 million dollars in upfront and near-term clinical milestone payments Novo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart disease ATTR cardiomyopathy Prothena Corporation plc and Novo Nordisk A/S today announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme. PRX004 is a phase 2ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associated with the disease pathology of ATTR amyloidosis. ATTR amyloidosis is a rare, progressive and fatal disease characterised by the abn…

Thermo Fisher Scientific, the world leader in serving science, today announced a collaboration with Ortho Clinical Diagnostics to promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS analyzers. Through this agreement, Ortho Clinical Diagnostics customers will have complete access to MAS third-party quality controls as well as the LabLink xL web-based quality assurance program that provides real-time quality control monitoring with automatic data entry upload and audit-friendly reports. Customers will also have access to additional features, including support, service and quality control ranges for specific reagent lots, unique features that are not currently available through any other quality…

The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction with empagliflozin for the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction (HFpEF) HFpEF has been classified as “the single largest unmet need in cardiovascular medicine”1 based on prevalence, poor outcomes and the absence of clinically proven therapies to date2 With approval, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of heart failure patients regardless of ejection fraction  The EMPEROR-Preserved Phase III trial met its primary endpoint, establishing empagliflozin as the first and only thera…

Alzheimer’s Research UK has been selected as the official 2021 charity partner of Hertfordshire-based company, Innovative Trials.  The company, which specialises in clinical trial patient recruitment and community engagement, is aiming to raise at least £5,000 for the charity over the next 12 months. The funds raised will support groundbreaking dementia research for a world free from the fear, harm, and heartbreak of dementia. In the UK, almost one million people are thought to be living with dementia and this is expected to rise to two million by 2050. Alzheimer’s Research UK is the UK’s leading dementia research charity committed to developing life-changing treatments and cures - a mission shared by Innovative Trials. Kate Shaw, founder and CEO of Innovative Trials, said: “Dementia is a…

BioMed X Institute expands its collaboration with Merck KGaA, Darmstadt, Germany to a total of eight research programs. Call for application of the new research program ‘Extrachromosomal DNA in Cancer’ to open now. Heidelberg, Germany, July 5, 2021 – BioMed X, a leading independent research institute, announced today the start of its eighth joint research program with Merck KGaA, Darmstadt, Germany. The new program will explore the role of extrachromosomal DNA in cancer and it will complement the research of two ongoing oncology programs at BioMed X in the fields of DNA damage response and RNA splicing. Extrachromosomal circular DNA (ecDNA) was recently found to be particularly abundant in multiple human cancer cells, although its frequency varies among different cancer types. Elevated l…